AACE/ACE disease state clinical review: Medical management of cushing disease

Endocrine Practice

Volumn 20, Issue 7, 2014, Pages 746-757

  Hamrahian, Amir H ^a   Yuen, Kevin C J ^b   Hoffman, Andrew R ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; ETOMIDATE; GLUCOCORTICOID RECEPTOR ANTAGONIST; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; PASIREOTIDE; RETINOIC ACID; CORTICOTROPIN; ERGOLINE DERIVATIVE; SOMATOSTATIN;

COMBINATION CHEMOTHERAPY; CUSHING DISEASE; CUSHING SYNDROME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDLINE; PREOPERATIVE CARE; REVIEW; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; METABOLISM; PITUITARY ACTH HYPERSECRETION; SECRETION (PROCESS);

ADRENOCORTICOTROPIC HORMONE; DRUG THERAPY, COMBINATION; ERGOLINES; HUMANS; KETOCONAZOLE; MIFEPRISTONE; PITUITARY ACTH HYPERSECRETION; SOMATOSTATIN;

EID: 84905007331     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP14147.RA     Document Type: Review

References (62)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367:1605-1617
2. Newell-Price J. Diagnosis/differential diagnosis of Cushing's syndrome: a review of best practice. Best Pract Res Clin Endocrinol Metab. 2009;23(suppl 1):S5-S14
3. Steffensen C, Bak AM, Rubeck KZ, Jørgensen JO. EpiDemiology of Cushing's syndrome. Neuroendocrinology. 2010;92(suppl 1):1-5
4. CAtargi B, Rigalleau V, Poussin A, et al. Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88:5808-5813
5. Chiodini I, Mascia ML, MusCArella S, et al. SubcliniCAl hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med. 2007;147:541-548
6. Reimondo G, Pia A, Allasino B, et al. Screening of Cushing's syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol (Oxf). 2007;67:225-229
7. Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropin syndrome: cliniCAl features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91:371-377
8. Sundaram NK, Carluccio A, Geer EB. Characterization of persistent and recurrent Cushing's disease. Pituitary. 2013, August 29. Epub ahead of print
9. Petersenn S, Newell-Price J, Findling JW, et al. High variability in baseline urinary free cortisol values in patients with Cushing's disease. Clin Endocrinol (Oxf). 2014;80:261-269
10. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-DepenDent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93: 2454-2462
11. Patil CG, PreveDello DM, Lad SP, et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008;93:358-362
12. Atkinson AB, Kennedy A, Wiggam MI, McCAnce DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63:549-559
13. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, SCanlon MF. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf). 2002;56:541-551
14. Xu Z, Lee Vance M, Schlesinger D, Sheehan JP. Hypopituitarism after stereotactic radiosurgery for pituitary aDenomas. Neurosurgery. 2013;72:630-637
15. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-DepenDent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93: 2454-2462
16. Sheehan JP, Xu Z, Salvetti DJ, Schmitt PJ, Vance ML. Results of gamma knife surgery for Cushing's disease. J Neurosurg. 2013;119:1486-1492
17. CAstinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009;160:1003-1010
18. Ritzel K, Beuschlein F, Mickisch A, et al. Outcome of bilateral adrenalectomy in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab. 2013;98:3939-3948
19. Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011;7:279-289
20. Hofland LJ, Van Der Hoek J, FeelDers R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph aDenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005; 152:645-654
21. Fleseriu M, Petersenn S. New avenues in the mediCAl treatment of Cushing's disease: corticotroph tumor targeted therapy. J Neurooncol. 2013;114:1-11
22. Nieman LK. Update in the mediCAl therapy of Cushing's disease. Curr Opin Endocrinol Diabetes Obes. 2013;20: 330-334
23. Van Der Pas R, De HerDer WW, Hofland LJ, FeelDers RA. Recent Developments in drug therapy for Cushing's disease. Drugs. 2013;73:907-918
24. Cohan P. PasireotiDe and mifepristone: new options in the mediCAl management of Cushing's Disease. Endocr Pract. 2014;20:84-93
25. Batista DL, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary aDenomas. J Clin Endocrinol Metab. 2006;91:4482-4488
26. BosCaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-DepenDent Cushing's disease with the multireceptor ligand somatostatin analog pasireotiDe (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009; 94:115-122
27. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotiDe in Cushing's disease. N Engl J Med. 2012;366:914-924
28. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Liqueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotiDe: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013; 98:3446-3453
29. Reznik Y, Bertherat J, Borson-Chazot F, et al. Management of hyperglyCAemia in Cushing's disease: experts' proposals on the use of pasireotiDe. Diabetes Metab. 2013;39:34-41
30. Stefaneanu L, Kovacs K, Horvath E, BuchfelDer M, Fahlbusch R, Lancranjan L. Dopamine D2 receptor gene expression in human aDenohypophysial aDenomas. Endocrine. 2001;14:329-336
31. PiVonello R, Ferone D, De HerDer WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452-2462
32. De Bruin C, FeelDers RA, Lamberts SW, Hofland LJ. Somatostatin and dopamine receptors as targets for mediCAl treatment of Cushing's Syndrome. Rev Endocr Metab Disord. 2009;10:91-102
33. Colao A, Lombardi G, Annunziato L. CAbergoline. Expert Opin Pharmacother. 2000;1:555-574
34. PiVonello R, Di Martino MC, CAppabianCA P, et al. The mediCAl treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist CAbergoline in patients unsuccessfully treated by surgery. J Clin Endorinol Metab. 2009;94:223-230
35. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. CAbergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163:709-716
36. Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of CAbergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary. 2010;13:123-129
37. Woo I, Ehsanipoor RM. CAbergoline therapy for Cushing disease throughout pregnancy. Obstet Gynecol. 2013;122: 485-487
38. SchaDe R, AnDersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of CArdiac-valve regurgitation. N Engl J Med. 2007;356:29-38
39. Melmed S, CAsanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society cliniCAl practice guiDeline. J Clin Endocrinol Metab. 2011; 96:273-288
40. Barake M, EVans AE, Stoeckel L, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. 2014;17: 150-156
41. BeVan JS, Webster J, Burke CW, SCAnion MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992; 13:220-240
42. Van Der Pas R, FeelDers RA, Gatto F, et al. Preoperative normalization of cortisol levels in cushing's disease after mediCAl treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. J Clin Endocrinol Metab. 2013;98:E1880-E1890
43. McCormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomiDe and the assessment of MGMT status. Eur J Clin Invest. 2011;41:1133-1148
44. Pecori Giraldi F, Ambrogio AG, Andrioli M, et al. Potential role for retinoic acid in patients with Cushing's disease. J Clin Endocrinol Metab. 2012;97:3577-3583
45. Engelhardt D, Weber MM. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol. 1994;49:261-267
46. Sonino N, BosCAro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf). 1991;35:347-352
47. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the mediCAl management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35:169-178
48. Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK. Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab. 2005;90:3077-3083
49. Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol. 2012;167:473-481
50. Luton JP, MahouDeau JA, Bouchard P, et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 CAses. N Engl J Med. 1979;300:459-464
51. Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med. 1980;92:613-619
52. Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hanke C, Winkelmann W. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr. 1988;66:361-364
53. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces cliniCAl and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-2049
54. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab. 2001;86:3568-3573
55. Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61: 536-540
56. Chrousos GP, Laue L, Nieman LK, et al. Glucocorticoids and glucocorticoid antagonists: lessons from RU 486. Kidney Int Suppl. 1988;26:S18-S23
57. Page ST, Krauss RM, Gross C, et al. Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function. J Clin Endocrinol Metab. 2012;97:1598-1605
58. Bertagna X, Guignat L. Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab. 2013;98: 1307-1318
59. Barbot M, Albiger N, CecCAto F, et al. Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with CAbergoline or ketoconazole? Pituitary. 2014;17:109-117
60. FeelDers RA, De Bruin C, Pereira AM, et al. PasireotiDe alone or with CAbergoline and ketoconazole in Cushing's disease. N Engl J Med. 2010;362:1846-1848
61. Kamenický P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-DepenDent Cushing's syndrome. J Clin Endocrinol Metab. 2011;96:2796-2804
62. Fukuoka H, Cooper O, Ben-Shlomo A, et al. EGFR as a therapeutic target for human, CAnine, and mouse ACTHsecreting pituitary aDenomas. J Clin Invest. 2011;121: 4712-4721.